REGN 1979

Drug Profile

REGN 1979

Alternative Names: REGN1979

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 03 Aug 2017 REGN 1979 receives Orphan Drug status for Diffuse large B cell lymphoma in USA
  • 03 Dec 2016 Interim efficacy, pharmakokinetics, pharmacodynamics and adverse event data from a phase I trial in Non-Hodgkin's lymphoma and Chronic lymphocytic leukemia (Second-line therapy or greater, Late-stage disease) presented 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2016)
  • 01 Dec 2015 Phase-I clinical trials in B-cell lymphoma in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top